{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:04:22Z","timestamp":1784952262517,"version":"3.55.0"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJHP"],"abstract":"<p><strong>ABSTRACT<\/strong><\/p><p><strong>Background:<\/strong> Thiamine (vitamin B1) is an essential cofactor responsible for the breakdown of glucose, and its deficiency is associated with Wernicke encephalopathy (WE). There is a lack of evidence from systematic studies on the optimal dosing of thiamine for WE.<\/p><p><strong>Objectives:<\/strong> The primary objective was to describe the prescribing patterns for IV thiamine in adult patients admitted to a large teaching hospital. The secondary objective was to evaluate the clinical resolution of WE symptoms (confusion, ataxia, and\/or ocular motor abnormalities) in<br \/>relation to the dose of IV thiamine prescribed.<\/p><p><strong>Methods:<\/strong> A retrospective design was used to review data for adult patients admitted to an internal medicine service from June 1, 2014, to June 30, 2015. All patients included in the study received IV thiamine: low-dose therapy was defined as 100 mg IV daily and high-dose therapy was defined as dosage greater than 100 mg IV daily.<\/p><p><strong>Results:<\/strong> A total of 141 patients were included; low-dose thiamine was prescribed for 115 (81.6%) and high-dose thiamine for 26 (18.4%). Patients for whom high-dose thiamine was prescribed were more likely to be those in whom a diagnosis of WE was being considered (12\/26<br \/>[46.2%] versus 5\/115 [4.3%], p &lt; 0.001). Of the total 219 IV thiamine doses ordered, 180 (82.2%) were for 100 mg, and 143 (65.3%) were prescribed for once-daily administration. There was no statistically significant difference in the time to resolution of WE symptoms for patients receiving high-dose versus low-dose thiamine.<\/p><p><strong>Conclusions:<\/strong> A wide variety of thiamine prescribing patterns were noted. This study did not show a difference in time to resolution of WE symptoms in relation to the dose of IV thiamine. Additional large-scale studies are required to determine the optimal dosing of thiamine for WE.<\/p><p><strong>R\u00c9SUM\u00c9<\/strong><\/p><p><strong>Contexte :<\/strong> La thiamine (vitamine B1) est un cofacteur essentiel responsable du m\u00e9tabolisme du glucose. Une carence en thiamine est associ\u00e9e \u00e0 l\u2019enc\u00e9phalopathie de Wernicke (EW). Or, on observe une absence de donn\u00e9es probantes provenant d\u2019analyses syst\u00e9matiques portant sur la<br \/>posologie optimale de thiamine dans le traitement de l\u2019EW.<\/p><p><strong>Objectifs :<\/strong> L\u2019objectif principal \u00e9tait de d\u00e9crire les habitudes de prescription de thiamine \u00e0 administrer par voie intraveineuse chez les patients adultes admis dans un important h\u00f4pital universitaire. L\u2019objectif secondaire \u00e9tait d\u2019\u00e9valuer la disparition clinique des sympt\u00f4mes de l\u2019EW (confusion, ataxie ou troubles moteurs oculaires) en fonction de la dose prescrite de thiamine \u00e0 administrer par voie intraveineuse.<\/p><p><strong>M\u00e9thodes :<\/strong> Un plan d\u2019\u00e9tude r\u00e9trospectif a \u00e9t\u00e9 utilis\u00e9 pour \u00e9tudier les donn\u00e9es concernant les patients adultes admis \u00e0 un service de m\u00e9decine interne entre le 1er juin 2014 et le 30 juin 2015. Tous les patients \u00e0 l\u2019\u00e9tude ont re\u00e7u de la thiamine par voie intraveineuse : le traitement \u00e0 faible dose \u00e9tait de 100 mg par jour et le traitement \u00e0 dose \u00e9lev\u00e9e exc\u00e9dait 100 mg par jour.<\/p><p><strong>R\u00e9sultats :<\/strong> Au total, 141 patients ont \u00e9t\u00e9 admis \u00e0 l\u2019\u00e9tude; l\u2019on a prescrit une faible dose de thiamine \u00e0 115 (81,6 %) d\u2019entre eux et une dose \u00e9lev\u00e9e aux 26 (18,4 %) autres. Les patients qui se sont vus prescrire une dose \u00e9lev\u00e9e de thiamine \u00e9taient vraisemblablement ceux pour qui l\u2019on envisageait un diagnostic d\u2019EW (12\/26 [46,2 %] contre 5\/115 [4,3 %], p &lt; 0,001). Pour l\u2019ensemble des 219 doses prescrites de thiamine \u00e0 administrer par voie intraveineuse, 180 (82,2 %) \u00e9taient de 100 mg et 143 (65,3 %) devaient \u00eatre inject\u00e9es \u00e0 une fr\u00e9quence uniquotidienne. On n\u2019a relev\u00e9 aucune diff\u00e9rence statistiquement significative quant au temps de disparition des sympt\u00f4mes de l\u2019EW entre les patients ayant re\u00e7u une dose \u00e9lev\u00e9e de thiamine et ceux en ayant re\u00e7u une faible dose.<\/p><p><strong>Conclusions :<\/strong> On a not\u00e9 une grande vari\u00e9t\u00e9 d\u2019habitudes de prescription de la thiamine. La pr\u00e9sente \u00e9tude n\u2019a pas montr\u00e9 que la dose de thiamine administr\u00e9e par voie intraveineuse changeait le temps n\u00e9cessaire \u00e0 la disparition des sympt\u00f4mes de l\u2019EW. Il est n\u00e9cessaire de mener de plus amples \u00e9tudes \u00e0 grande \u00e9chelle afin de d\u00e9terminer quelle est la posologie optimale de thiamine dans le traitement de l\u2019EW.<\/p><\/jats:p>","DOI":"10.4212\/cjhp.v70i3.1657","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T16:20:40Z","timestamp":1499790040000},"source":"Crossref","is-referenced-by-count":16,"title":["Thiamine Prescribing Practices for Adult Patients Admitted to an Internal Medicine Service"],"prefix":"10.4212","volume":"70","author":[{"given":"Uzma","family":"Alim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashten","family":"Langevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Werry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deonne","family":"Dersch-Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcy","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2732","published-online":{"date-parts":[[2017,6,30]]},"container-title":["The Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"http:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/viewFile\/1657\/2551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/viewFile\/1657\/2570","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/viewFile\/1657\/2570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T16:20:42Z","timestamp":1499790042000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/1657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,6,30]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.v70i3.1657","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"value":"1920-2903","type":"electronic"},{"value":"0008-4123","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,30]]}}}